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Introduction
Systemic embolization occurs in approximately 22-50% of 
cases of infective endocarditis (IE) and up to 65% of embolic 
events involve the central nervous system (CNS).1) In patients 
with embolic stroke, anticoagulation therapy may lead to 
hemorrhagic transformation (HT) and consequently worsen 
prognosis and severity of neurologic symptoms. It has been re-
ported that hemorrhagic events occur in 51-71% of embolic 
strokes and thus occur more frequently than in non-embolic 
strokes (2-21%).2-4) The location, size, and cause of stroke can 
influence the development of HT, and the use of antithrom-
botic medications - especially anticoagulant and thrombolytic 
agents - can increase the likelihood of HT.5)6) In general, man-
agement of patients with HT depends on the amount of 
bleeding and clinical symptoms.
In patients with native valve IE, anticoagulation is typically 
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Background: Hemorrhagic transformation (HT) of stroke is a disastrous complication in patients with infective endocarditis 
(IE). In patients with mechanical heart valves complicated by IE, physicians struggle with the appropriateness of anticoagulation 
administration given the risk of thromboembolism and HT of stroke. In this study, we aimed to define predictive parameters of 
HT of stroke in patients with prosthetic valve endocarditis (PVE).
Methods: This study was a multicenter, retrospective design. We recruited from 7 institutions a total of 111 patients diagnosed 
with PVE during May, 2011 to April, 2012.
Results: Complication of stroke was seen in 26/111 patients (23%), and HT of stroke was seen in 11/111 patients (10%). 
Most patients with HT (9/11, 82%) had supratherapeutic prothrombin times. However, there were no significant differences in 
clinical and laboratory values between PVE patients without stroke and those patients who had a stroke and with or without 
concurrent HT. Furthermore, echocardiographic parameters also did not show significant between-group differences.
Conclusion: Even though this was a multicenter study, a limited number of patients was identified and may explain the 
negative results seen here. However, a large number of PVE patients with stroke also developed HT. Therefore, further studies to 
define predictive parameters of HT should be implemented in a larger population.
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not recommended as the benefits have never been fully demon-
strated.1)3) Conversely, in prosthetic valve endocarditis (PVE), 
some authorities recommend continuation of anticoagulation 
to prevent thrombotic complications.7) However, in specific 
circumstances such as patients with PVE caused by Staphylo-
coccus aureus (S. aureus) and a recent CNS embolic event, it is 
generally advised to hold all anticoagulation therapy during 
the first 2 weeks of antibiotic treatment.1) Thrombus organiz-
es during this period and discontinuing anticoagulants helps 
to prevent acute HT. Anticoagulation therapy should then be 
restarted cautiously, and prothrombin time (PT) should be 
monitored carefully.3)
Since HT exacerbates functional disability and worsens 
overall prognosis for stroke patients, clinicians remain ambiv-
alent about maintaining anticoagulation in cases of ischemic 
stroke in PVE.5)8-11) However, no consensus exists regarding 
discontinuation of anticoagulation in PVE complicated by 
ischemic stroke but with pathogens other than S. aureus.12)13)
Therefore, we evaluated embolic stroke and HT in patients 
with PVE and investigated clinical and echocardiographic 
predictors for HT of ischemic stroke in following PVE.
Methods
Patients
We retrospectively reviewed clinical records and echocardio-
graphic images of 156 patients from 7 institutions who were 
diagnosed with PVE during May, 2011 to April, 2012. Par-
ticipating centers included Severance Hospital, Seoul National 
University Hospital, Samsung Medical Center, Pusan Nation-
al University Hospital, Yeungnam National University Hos-
pital, Bundang CHA Medical Center, and Gangnam Sever-
ance Hospital. Patients with bioprosthetic valves (n = 43) or 
with insufficient medical records (n = 2) were excluded. In to-
tal, 111 PVE patients with mechanical valves comprised the 
study population. Occurrence of redo-valve replacement sur-
gery and in-hospital mortality was checked by reviewing hos-
pital records.
The presence of ischemic stroke and development of HT 
were diagnosed by imaging studies in symptomatic patients. 
Brain imaging studies were read by an experienced neuroradi-
ologist with extensive experience in evaluating acute stroke. 
The brain was divided into 3 vascular territories according to 
the blood supply: left internal carotid artery, right internal ca-
rotid artery, and vertebrobasilar supply. A multivessel stroke 
was defined as the presence of involvement in more than one 
vascular territory.10) HT was defined as secondary bleeding of 
ischemic stroke, ranging from small areas of petechial hemor-
rhage to massive space-occupying hematomas.11)
Two-dimensional echocardiography  
with Doppler
Transesophageal echocardiography (TEE) was performed on 
all patients. Echocardiographic studies were conducted during 
the acute phase of IE. Two experienced echocardiographers in-
dependently reviewed TEE studies without knowledge of pa-
tient history or subsequent clinical course. Echocardiographic 
data were classified using Duke criteria.14) Echocardiographic 
characteristics of IE included vegetation, abscess, new partial de-
hiscence of the prosthetic valve, valve perforation, and new valve 
regurgitation. Perivalvular abscess was defined as a thickened 
area or mass in the myocardium or annular region with a non-
homogeneous appearance.15) Transvalvular pressure gradient 
was measured using continuous wave Doppler. Severe ob-
struction was defined as mean diastolic pressure gradient > 10 
mmHg, peak velocity ≥ 2.5 m/s, and pressure half time > 200 
sec in patients with prosthetic mitral valve; and mean systolic 
pressure gradient > 35 mmHg and peak velocity ≥ 4 m/s in 
patients with prosthetic aortic valve. Pulmonary hypertension 
was defined as calculated right ventricular systolic pressure ≥ 
35 mmHg.
Assessment of vegetations
Vegetation was defined as a fixed or oscillating mass adher-
ent to a leaflet or other cardiac structure with a distinct echo-
genic appearance and independent motion. The lesion had to 
be visible in multiple views and detectable during the com-
plete cardiac cycle. Vegetation measurements were obtained 
in various planes with the maximal length used. When multi-
ple vegetations were present, the largest value was used for 
analysis. Vegetation mobility was evaluated using a 4-point 
scale defined as: 0 = fixed vegetation with no detectable inde-
pendent motion; 1 = vegetation with a fixed base but with a 
mobile free edge; 2 = pedunculated vegetation that remains 
within the same chamber throughout the cardiac cycle; and 3 
= prolapsing vegetations that cross the coaptation point of the 
leaflets during the cardiac cycle.16)
Statistical analysis
Relevant variables were reported either as percentages or as 
means ± standard deviations. Groups were compared using χ2 
statistics for categorical variables and Student’s t-tests for con-
tinuous variables. If the distributions were skewed, a non-para-
metric test such as Mann-Whitney U-test and Kruskal-Wallis 
test were used. A p-value < 0.05 was considered statistically sig-
nificant.
Results
Demographic and clinical characteristics of the study popu-
lation are shown in Table 1. Mean age was 54 ± 12 years-old, 
and 54% of the patients were male. Redo-valve replacement 
surgery was performed in 57 patients, and in-hospital mortali-
ty occurred in 12 patients. Among the 111 patients with PVE, 
26 patients (23%) suffered ischemic stroke due to IE. HT was 
observed in 11 of those 26 patients who developed ischemic 
stroke (Fig. 1).
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Clinical characteristics of PVE patients with and without 
stroke are summarized in Table 2. There were no significant dif-
ferences in age, gender, prevalence of hypertension, diabetes and 
atrial fibrillation, involved valve, time interval between opera-
tion and diagnosis of IE, duration of hospital stay, initial vital 
signs and laboratory findings, necessity of redo-valve surgery, 
mortality, or pathogen type between patients with and without 
stroke. Platelet count was higher in stroke patients (p = 0.013). 
Redo-valve replacement surgery was performed in 17 patients 
with stroke; causes for reoperation were persistent fever and veg-
etation (n = 7), valve dehiscence (n = 6), perivalvular abscess (n 
= 2), heart failure (n = 1), and valve stenosis (n = 1). There were 
4 deaths including 3 cases of shock due to uncontrolled infec-
tion and 1 case with critical intracranial hemorrhage.
We also compared variables between stroke patients with 
and without HT (Table 2). Stroke with concurrent HT was 
seen in 8 of 11 patients (73%). There were no significant dif-
ferences in age, gender, prevalence of hypertension, diabetes 
and atrial fibrillation, involved valve, time interval between 
operation and diagnosis of IE, duration of hospital stay, vital 
signs and laboratory findings at initial presentation and at 
time of stroke occurrence, and necessity of redo-valve opera-
tion. There were no significant differences in the vascular ter-
ritory of stroke between the groups. In-hospital mortality and 
S. aureus infections were more common in stroke patients with 
HT compared with stroke patients without HT, although no 
statistically significance differences were observed (27% vs. 
7%, p = 0.150; 36% vs. 13%, p = 0.381; respectively). Most 
stroke patients with HT had supratherapeutic PT values (9/11 
patients, 82%), but there was no statistical difference in PT 
between-groups.
Table 3 shows the comparison of echocardiographic parame-
ters between stroke patients with and without HT. There 
were no significant differences between-groups in number, 
size, and mobility of vegetations. Left ventricular ejection frac-
tion, severe valve dysfunction, and complications of IE includ-
ing perivalvular abscess and valve dehiscence were not statisti-
cally different between-groups. Pulmonary hypertension was 
more common in stroke patients with HT, although it did not 
achieve statistical significance (64% vs. 27%, p = 0.059).
Comparisons between stroke patients caused by S. aureus or 
by other organisms are shown in Table 4. There were no sig-
nificant differences in reoperation, duration of hospital stay, 
Table 1. Patient characteristics
Characteristics Value
Number of patients 111
Age (yr)   54 ± 12
Males 60 (54)
Hypertension 15 (14)
Diabetes mellitus 10 (90)
Atrial fibrillation 38 (34)
Involved valve
    Mitral 35 (32)
    Aortic 30 (27)
    Combined mitral and aortic 40 (36)
    Other 6 (5)
Time interval between operation and  
  diagnosis of infective endocarditis
    < 60 days 17 (15)
    ≥ 60 days 94 (85)
    Mean time interval (months)   95.2 ± 95.3
Duration of hospital stay (days)   42.8 ± 25.7
Initial vital signs
    Systolic blood pressure (mmHg) 113.8 ± 17.3
    Diastolic blood pressure (mmHg)   66.8 ± 13.7
    Heart rate (beats/min)   85.3 ± 19.7
Initial PT/INR   2.77 ± 2.26
Initial aPTT (sec)   59.6 ± 26.3
Hemoglobin (g/dL)   10.7 ± 2.2
WBC (cells/µL)   11.9 ± 7.8
Platelets (cells/µL)   200 ± 103
Reoperation 57 (51)
In-hospital mortality 12 (11)
Pathogen type
    Staphylococcus aureus 18 (16)
    Other* 56 (51)
    Negative blood cultures 36 (33)
Stroke 26 (23)
Hemorrhagic transformation 11 (10)
Data are presented as n (% of population) or mean ± standard deviation. 
*Includes 12 other Staphylococcus species, 23 Streptococcus species, 6 Enterobacter 
species, 4 Pseudomonas species, 3 Escherichia coli species, 2 Corynebacterium 
species, 1 Acinetobacter baumannii, 1 Brucellosis, 1 Haemophilus influenza, 1 
HACEK, 1 Micrococcus, and 1 Alcaligenes xylosoxidans. PT: prothrombin time, 
INR: international normalized ratio, aPTT: activated partial thromboplastin 
time, WBC: white blood cell
Fig. 1. Study population.
Hemorrhagic transformation (+) (n = 11, 10%)
Ischemic stroke (+) (n = 26, 23%)
Hemorrhagic transformation (-) (n = 15, 14%)
Ischemic stroke (-) (n = 85, 77%)
Prosthetic valve endocarditis (n = 111)
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PVE patients with stroke (n = 26)
p-value*
All (n = 26) HT (-) (n = 15) HT (+) (n = 11) p-value†
Age (yr)   53.7 ± 12.9 54.5 ± 9.5 53.5 ± 8.2   55.8 ± 11.2 0.782 0.856
Males 47 (55) 13 (50)   8 (53)   5 (46) 0.635 0.826
Hypertension   9 (11)   6 (23)   2 (13)   4 (36) 0.348 0.103
Diabetes mellitus 8 (9) 2 (8) 1 (7) 1 (9) 0.999 0.789
Atrial fibrillation 29 (34)   9 (35)   5 (33)   4 (36) 0.999 0.963
Involved valve 0.875 0.813
    Mitral 26 (31)   9 (35)   5 (33)   4 (36)
    Aortic 22 (26)   8 (31)   6 (40)   2 (18)
    Combined mitral and aortic 32 (38)   8 (31)   4 (27)   4 (36)
    Other 5 (6) 1 (4) 0 (0) 1 (9)
Time interval between operation and 
  diagnosis of infective endocarditis
    < 60 days 13 (15)   4 (15)   3 (20) 1 (9) 0.603 0.747
    ≥ 60 days 72 (85) 22 (85) 12 (80) 10 (91)
    Mean time interval (months)   97.2 ± 96.6   88.8 ± 89.8   80.9 ± 85.2   99.6 ± 99.0 0.695 0.820
Duration of hospital stay (days)   40.4 ± 25.9   50.1 ± 24.1   47.1 ± 22.0   54.1 ± 27.3 0.095 0.197
Initial vital signs and laboratory findings
    Systolic blood pressure (mmHg) 112.4 ± 17.6 118.0 ± 15.3 117.7 ± 15.8 118.2 ± 16.3 0.154 0.363
    Diastolic blood pressure (mmHg)   66.7 ± 13.6   67.5 ± 14.1   66.6 ± 16.2   67.5 ± 11.7 0.802 0.969
    Heart rate (beats/min)   86.7 ± 19.9   81.2 ± 18.6   85.9 ± 18.8   76.5 ± 18.6 0.237 0.281
    PT/INR   2.80 ± 2.44   2.64 ± 1.53   2.63 ± 0.98   2.77 ± 2.11 0.760 0.926
    aPTT (sec)   61.8 ± 28.1   51.8 ± 17.6   50.9 ± 14.2   54.0 ± 27.8 0.097 0.239
    Hemoglobin (g/dL) 10.9 ± 2.2   9.9 ± 1.9 10.0 ± 1.6   9.8 ± 2.2 0.073 0.198
    WBC (cells/µL) 11.9 ± 8.4 11.7 ± 4.8 10.8 ± 3.5 12.7 ± 6.0 0.914 0.844
    Platelets (cells/µL) 185 ± 86   257 ± 141   255 ± 117   260 ± 173 0.742 0.013
Vital signs and laboratory findings at stroke
    Systolic blood pressure (mmHg) 112.8 ± 10.6 118.9 ± 15.9 0.250
    Diastolic blood pressure (mmHg)   65.7 ± 15.3   70.2 ± 10.7 0.417
    Heart rate (beats/min)   84.0 ± 17.9   82.1 ± 15.8 0.781
    PT/INR   2.1 ± 0.9   2.5 ± 1.6 0.407
    aPTT (sec)   56.6 ± 18.1   57.8 ± 30.7 0.912
    Hemoglobin (g/dL)   9.9 ± 1.8   9.4 ± 2.6 0.657
    WBC (cells/µL) 10.9 ± 4.6 11.5 ± 6.1 0.828
    Platelets (cells/µL)   238 ± 134   219 ± 161 0.739
Reoperation 40 (47) 17 (65) 11 (73)   6 (55) 0.102 0.168
In-hospital mortality 8 (9)   4 (15) 1 (7)   3 (27) 0.391 0.171
Pathogen type 0.381 0.460
    Staphylococcus aureus 12 (14)   6 (23)   2 (13)   4 (36)
    Other‡ 44 (52) 12 (46)   8 (53)   4 (36)
    Negative blood cultures 28 (33)   8 (31)   5 (33)   3 (27)
Vascular territory of stroke 0.617
    Left internal carotid artery   5 (33)   2 (18)
    Right internal carotid artery   3 (20) 1 (9)
    Vertebrobasilar artery 1 (7) 1 (9)
    Multivessel territory   6 (40)   7 (64)
Data are presented as n (% of population) or mean ± standard deviation. *Statistical significance of values between prosthetic valve endocarditis with and 
without stroke, †Statistical significance of values between stroke patients with and without hemorrhagic transformation, ‡Includes 12 other Staphylococcus 
species, 23 Streptococcus species, 6 Enterobacter species, 4 Pseudomonas species, 3 Escherichia coli species, 2 Corynebacterium species, 1 Acinetobacter baumannii, 1 
Brucellosis, 1 Haemophilus influenza, 1 HACEK, 1 Micrococcus, and 1 Alcaligenes xylosoxidans. PVE: prosthetic valve endocarditis, HT: hemorrhagic transformation, 
PT: prothrombin time, INR: international normalized ratio, aPTT: activated partial thromboplastin time, WBC: white blood cell
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white blood cell count, PT, and activated partial thromboplas-
tin time between-groups. Platelet count was significantly lower 
in PVE patients caused by S. aureus (p = 0.039). HT was more 
common and hemoglobin level was lower in the S. aureus 
group, but no statistically significant differences were identi-
fied (67% vs. 35%, p = 0.169; 11.2 mg/dL vs. 9.4 mg/dL, p = 
0.050, respectively).
Discussion
The current study demonstrated that 1) embolic stroke was 
seen in about a quarter of patients with PVE (26/111 patients, 
23%), 2) nearly half of embolic strokes in PVE patients were 
accompanied by HT (11/26 patients, 42%), 3) in-hospital 
mortality of PVE patients with embolic stroke was 15% (4/26 
patients), 4) in-hospital mortality appeared higher in patients 
with HT compared to those without HT (27% vs. 7%), al-
though statistically significant differences were not identified 
likely due to the limited number of patients identified for 
study, and 5) predictors for HT of ischemic stroke were not 
identified from the present study, even though we recruited 
patients through a multicenter study. 
Stroke remains a debilitating complication of left-sided IE in 
20-40% of patients and has been associated with poor out-
comes.17) In the present study, stroke was seen in 23% of PVE 
patients, a proportion similar to previous reports of IE patients.9) 
As a result, we speculate that the risk of stroke may not be in-
fluenced by the type of infected valve (native vs. prosthetic). 
Not surprisingly, HT was observed in nearly half of embolic 
patients as prior evidence demonstrated increased frequency of 
HT in embolic stroke than in non-embolic stroke patients. 
Mortality rate for our overall data was 11% and 15% in stroke 
patients. Interestingly, mortality rate of stroke patients with-
out HT appeared much lower than stroke patients with HT 
(7% vs. 37%). Therefore, stroke following IE of mechanical 
heart valves might represent a poor prognostic factor, specifi-
cally when associated with HT.
PT values were not different between stroke patients with 
and without HT both at the onset of IE and at stroke presen-
tation. Although most of the patients with HT had suprather-
apeutic PT values (PT/INR > 3), HT also occurred in 2 pa-
tients with suboptimal PT levels. Therefore, other factors yet 
to be uncovered may also be associated with the development 
of HT in PVE. PT levels remained prolonged even after dis-
continuing anticoagulation in most of our patients - perhaps 
due to uncontrolled infection - suggesting that the clinical ben-
efits of stopping anticoagulants in PVE patients with elevated 
PT values remain unknown. In our population, 8 of 11 stroke 
patients (73%) were complicated with HT at the time of 
Table 3. Comparison of echocardiographic variables between stroke patients with and without hemorrhagic stroke
PVE patients with stroke (n = 26)
p-value
HT (-) (n = 15) HT (+) (n = 11)
Ejection fraction < 55%   4 (27)   4 (36) 0.597
Number of vegetation (s)   1.8 ± 1.1   1.4 ± 0.9 0.317
Vegetation size (mm) 11 ± 4 10 ± 4 0.554
Mobility scale of vegetation   2.0 ± 0.8   2.0 ± 0.7 0.800
Perivalvular abscess   5 (33)   2 (18) 0.390
Valve dehiscence   3 (20)   3 (27) 0.664
Severe valve regurgitation   2 (13) 1 (9) 0.738
Severe valve obstruction 1 (7) 0 (0) 0.382
Pulmonary artery hypertension   4 (27)   7 (64) 0.059
Data are presented as n (% of population) or mean ± standard deviation. PVE: prosthetic valve endocarditis, HT: hemorrhagic transformation
Table 4. Comparison between stroke patients caused by Staphylococcus aureus and other organisms
S. aureus (n = 6) Other organisms (n = 20) p-value
Hemorrhagic transformation 4 (67)   7 (35) 0.169
Reoperation 4 (67) 13 (65) 0.940
In-hospital mortality 2 (33) 10 (10) 0.165
Duration of hospital stay (days)   61 ± 32   52 ± 22 0.639
Hemoglobin (g/dL) 11.2 ± 0.9   9.4 ± 1.9 0.050
WBC (cells/µL) 13.1 ± 6.8 11.7 ± 4.6 0.914
Platelets (cells/µL) 144 ± 57   275 ± 145 0.039
PT/INR   2.2 ± 0.8   2.5 ± 1.2 0.779
aPTT (sec) 49 ± 8 43 ± 9 0.160
Data are presented as n (% of population) or mean ± standard deviation. WBC: white blood cell, PT: prothrombin time, INR: international normalized ratio, 
aPTT: activated partial thromboplastin time
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stroke diagnosis, demonstrating the difficulty in preventing 
HT by discontinuing anticoagulation. 
IE caused by S. aureus has the worst prognosis and has a 
high rate of embolic episodes with subsequent neurologic in-
volvement.18)19) Therefore, we compared differences between 
stroke patients with S. aureus infection and stroke patients in-
fected by other organisms. HT of ischemic stroke was seen 
more commonly in PVE caused by S. aureus than by other 
pathogens (67% vs. 35%). Platelet count was much lower 
with S. aureus infection, which may indicate a possible role of 
sepsis in the development of HT of ischemic stroke. There-
fore, results from the present study support the discontinua-
tion of anticoagulant therapy in patients with PVE caused by 
S. aureus due to the high occurrence of HT of embolic stroke 
seen in our data.
The main limitation of this study was the small patient pop-
ulation and retrospective analysis. Limited number of cases 
may have caused the negative results seen here. Clinical detec-
tion alone of embolic stroke clearly underestimates the true 
prevalence. Furthermore, many of the patients diagnosed with 
IE and ischemic stroke simultaneously at the time of hospital 
admission likely had echocardiographic examinations per-
formed at varying stages of endocarditis development. There-
fore, the predictive value of echocardiography for stroke and 
HT may be limited. Further prospective studies to define pa-
rameters of HT should be implemented in a larger population 
to help clarify the optimal care of PVE patients with ischemic 
stroke.
In conclusion, although we identified patients through a 
multicenter study, a limited number of cases likely impacted 
the negative results seen here. However, a large number of pa-
tients with PVE who suffered a stroke subsequently had HT. 
Therefore, further studies to define predictive parameters of 
HT should be implemented in a larger population.
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